It's going to be a long slog for sure. I believe, however, that we'll get to profitability sooner than later. Take care! Of course, I've reentered at $1.41 so it's a bit different for me.
200 contributor followers says low impact but the argument was well framed and rebuttals few. I therefore predict 4-7% lower by days end on heavy volume.
It's then received the "Pro" designation. Don't count on it being an endorsement of ACTC. OT could be a short piece. And depending on the author's stature and number of followers could have no effect or move the stock 10% in either direction.
Auger, that made me laugh so hard. You really did watch my video. That free riding four is down I think about 20 cents. Because it's a small position by anyone's standard, I'm content to ignore it while this all plays out. For those, like yourself, who've bought in for some time now, I'm just hoping that you get the just reward you deserve. And that's delivery on what's been promised. Without that, this company will head the list of most dishonorable biotechs. Unfortunately, that's not a short list in this sector.
pk ~ just when I thought John Thero was the worst CEO a company could have, along you come with this idea and I feel immeasurably better. Thank you!
Karl.todd please forgive me. When I write I do so rhetorically and rarely in response to an individual. My "get over it" was addressed to those holding the thought that dilution is an evil in and of itself. It isn't! It's a necessity and the how of it is the only matter of importance. Good post on your part! And again, I'm sorry for the misunderstanding.
Vote no and the company will be forced into bankruptcy. Biotech's need operating cash. Get over it! The name change makes complete sense. Let's just hope that promised NEJM article comes soon. Me entire investment thesis is predicted upon that and uplisting. If both occur prior to November 7th the stock will trade at over $20. If after, at over $15.
Yes! I don't care that chart analysis has as much to do with biotech as horse racing has to do with childcare because I know that someone, somewhere is changing a diaper in a small town diner straining to view a tiny b&w monitor while holding the ticket to #4 in one hand as the other hand is deftly slimed in #2. Cup-n-Handle baby! Cup-n-Handle.
Hey! Thanks very much auger2k. I keep telling myself to exit all forum participation for peace of mind, but this one is too much fun. My favorite dude here is jsmitty. I know he's a hedge fund hack but he's a funny HFH and he never takes things personally. I can see we're here for similar reasons. Thanks again!
keep-investing and jsmitty won't be with us for a few days because they won't want to explain how they caused you to miss out on $24 a share. And how could you blame them? For them, it will be like losing all over again. Some investors should simply steer clear of biotech. They simply can't make money and so they spend their time insisting that you don't either. Be smarter! Be ScryingBiotech!
jsmitty ~ they're livin' large on your money man. Right now, Lanza is christening a cloned, new borne baby raptor named Smitty and laughing his fluffing #$%$ off. He's got a whole section of the dead bone yard named keep-investing where he and Gary Rubin read your cry baby posts back and forth in drunken reverie unable to determine which one is the lamest and exactly how many of your dollars they spent on the last case of cellared wine they bought. Me? I've made money here. Learn how at scryingbiotech.
dinobonescostumbigbucks - hilarious! Note: I'm long but appreciate good humor wherever I find it.
The nice thing about you baby girl is its so cute how you're always wrong. Yes, the price will track lower as previously indicated, but 102 is designed for success. There's virtually no threshold to meet. Any positive numbers will result in approval. Stock will be $12 in mid-November and $25 in February. And by the way, it hurts that I'm always right.
The only problem with that scenario is that Thero won't sell to GSK because he knows they purposefully undermined Amarin at adcom.